Capivasertib is a serine/threonine kinase inhibitor used to treat hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. Hormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually.
- Mechanism
- Curator reviewed · 1 reference
Capivasertib is an inhibitor of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2, and AKT3) and inhibits phosphorylation of downstream AKT substrates. AKT activation in tumors is a result of activation of upstream signaling pathways, mutations in AKT1, loss of phosphatase and tensin homolog (PTEN) function, and mutations in the catalytic subunit alpha of phosphatidylinositol 3-kinase (PIK3CA).
- Primary indication
- Capivasertib, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration...Curator reviewed · 2 structured indications
- Formula / weight
- C21H25ClN6O2 · 428.915 g/mol (avg)
- First approval
- Canada, 2024 · United States, 2023 · European Union, 2024
- Code names
- AZD-5363
- Brand names
Resolves to
JDUBGYFRJFOXQC-KRWDZBQOSA-NSMILESNC1(CCN(CC1)C1=C2C=CNC2=NC=N1)C(=O)N[C@@H](CCO)C1=CC=C(Cl)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Capivasertib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account